Kronox Lab Sciences falls 3.1% as ₹157.27 open-offer price disappoints investors

According to the Letter of Offer (pages 2, 10–12 and 22–24):

• Indo Borax and Chemicals Limited (the Acquirer) and Zenrock Chemicals Private Limited (the PAC) are making an open offer to public shareholders of Kronox Lab Sciences Limited for up to 95,70,000 equity shares.
• These shares have a face value of ₹10.00 each and represent 25.79% of the Voting Share Capital.
• The Offer Price is fixed at ₹157.27 per share, payable in cash.
• The maximum cash outlay, assuming full acceptance, is Rs 150.51 cr (the “Maximum Consideration” / “Maximum Open Offer Consideration”).
• The offer is mandatory under Regulations 3(1) and 4 of the SEBI (SAST) Regulations, triggered by a change of control.

The filing also confirms (Section III, Part A, paragraphs 2 and 8):

• Indo Borax has already acquired 2,38,44,000 Kronox shares from the outgoing promoters via a Share Purchase Agreement (SPA) dated August 20, 2026, amended October 22, 2026.
• Those 2,38,44,000 shares represent 64.26% of the total paid-up equity share capital on a fully diluted basis.
• The SPA price is ₹103.22 per share, with an effective negotiated price of ₹105.87 per share after adding a consultancy component under Regulation 8(7).
• The sellers now retain 36,90,000 shares, or 9.95% of Voting Share Capital, and have been reclassified from promoter group to public as of September 29, 2026.

The key reason the stock eased is that the open-offer economics look unattractive relative to where Kronox has been trading.

The Letter of Offer (Section VII, Offer Price and Financial Arrangements) makes clear that:

• The Offer Price of ₹157.27 per share is derived under Regulation 8(1), 8(2) and 8(7) of the SEBI (SAST) Regulations.
• One of the key reference points is the volume-weighted average market price over the 60 trading days before the public announcement, which the filing states works out to ₹157.27 (row D of the pricing table on page 44).
• By contrast, the negotiated control block changed hands at an effective ₹105.87 per share (SPA price of ₹103.22 plus ₹2.65 per share equivalent consultancy fee), as detailed on pages 17–18 and 43–45.

In other words, the open-offer price is anchored to the historical trading average, not to the current market level. With Kronox last traded at Rs 190, the offer now sits at a visible discount to the live screen price.

That matters for three reasons:

1. No exit premium for minorities
   The Letter of Offer explicitly states (Section III, Part B, point 11) that the open offer is not conditional on any minimum level of acceptance. But with an offer price of ₹157.27 against a market price around Rs 190, there is little economic incentive for ordinary shareholders to tender.

2. Control premium is being priced in the market, not in the offer
   The SPA shows Indo Borax secured control at ₹103.22 per share, plus a total consultancy fee of Rs 6.30 cr payable by the company to the outgoing promoters over 36 months (Definitions, “Consultancy Fee” and Section III.A.3). That consultancy element is already baked into the regulatory pricing formula, but the open-offer price still comes out far below where the stock trades now.
   The market appears to be valuing the new promoter’s strategic plans and Kronox’s standalone fundamentals above both the SPA price and the computed offer price, and Tuesday’s move reflects investors recalibrating to the reality that there is no near-term cash takeout at a premium.

3. Ceiling on near-term upside
   While the Acquirer has reserved the right to revise the Offer Price upwards before the last working day prior to the tendering period (Section VII, points 8, 10 and 11), the Letter of Offer also notes that as of October 29, 2026 there is no revision in price or size. That effectively sets a reference point: any sharp rally much above current levels is unlikely to be supported by the open-offer floor, because that floor is well below the market.

The live market read referenced by the filing’s timing suggests traders are treating the Letter of Offer as confirmation that the open offer is a formality rather than a lucrative exit route, prompting some profit-taking after a strong run since listing.

Even if the open-offer price disappoints, the control change is significant.

From the Letter of Offer (Section IV and VI):

• Indo Borax is a listed specialty chemicals player itself, with consolidated revenue from operations of Rs 215.45 cr in FY 2025–26 and profit after tax of Rs 50.27 cr (page 32).
• Kronox, meanwhile, reported revenue from operations of Rs 101.22 cr and profit after tax of Rs 27.66 cr in FY 2025–26, with Q1 FY27 (three months ended June 30, 2026) revenue of Rs 28.39 cr and profit after tax of Rs 7.30 cr (pages 40–42).
• The acquirer has already reconstituted the Kronox board as of September 29, 2026, with Indo Borax representatives including Sunil Malhotra, Suresh Kalra and Harsh Malhotra now on the Kronox board (page 41).

The document also states (Section III.C.1–3) that Indo Borax’s stated objective is to use the acquisition to expand operations, diversify its portfolio and “nurture and expand the Target Company’s business,” and that it does not currently intend to dispose of material assets for at least two years, except under specific conditions.

Those strategic and governance changes are part of why the market has been willing to value Kronox well above both the SPA price and the open-offer price. But they are longer-term drivers; Tuesday’s 3.1% intraday decline reflects the shorter-term reality that:

• The open offer is priced at ₹157.27, not at a premium to the current market.
• The entire public float of 95,70,000 shares (25.79% of Voting Share Capital) is eligible, but there is no minimum acceptance condition.
• The Acquirer has already secured 64.26% control, so the offer is a regulatory requirement rather than a price-discovery event.

Within the strict confines of the Letter of Offer:

• There is no explicit guidance on future earnings, synergies or cost savings from integrating Kronox with Indo Borax.
• The document does not break out margin percentages for Kronox; it only provides revenue, total income, expenditure and profit figures.
• There is no discussion of analyst target changes or valuation benchmarks.

That means the 3.1% slide to Rs 190 cannot be tied to any fresh deterioration in fundamentals disclosed in this filing. Instead, the move appears to be driven by the market’s reassessment of the risk–reward around the open-offer terms now that the final Letter of Offer confirms a cash exit price that is materially below where the stock trades.

For now, the open offer sets a regulatory floor at ₹157.27, but the market is clearly choosing to value Kronox above that level — and Tuesday’s reaction reflects disappointment that the offer itself is not the catalyst for an immediate premium exit.